REPLIMUNE GROUP INC (REPL)
US76029N1063 - Common Stock
REPL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 574 industry peers in the Biotechnology industry. The financial health of REPL is average, but there are quite some concerns on its profitability. REPL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year REPL has reported negative net income.
REPL had a negative operating cash flow in the past year.
In the past 5 years REPL always reported negative net income.
In the past 5 years REPL always reported negative operating cash flow.
1.2 Ratios
REPL has a Return On Assets (-41.13%) which is comparable to the rest of the industry.
REPL has a Return On Equity of -51.59%. This is in the better half of the industry: REPL outperforms 65.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.13% | ||
| ROE | -51.59% | ||
| ROIC | N/A |
ROA(3y)-32.26%
ROA(5y)-26.83%
ROE(3y)-39.24%
ROE(5y)-32.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
REPL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, REPL has more shares outstanding
The number of shares outstanding for REPL has been increased compared to 5 years ago.
The debt/assets ratio for REPL is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.54, we must say that REPL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.54, REPL is in the better half of the industry, outperforming 68.49% of the companies in the same industry.
REPL has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.16, REPL is not doing good in the industry: 66.90% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.54 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 13.46 indicates that REPL has no problem at all paying its short term obligations.
REPL's Current ratio of 13.46 is amongst the best of the industry. REPL outperforms 85.92% of its industry peers.
A Quick Ratio of 13.46 indicates that REPL has no problem at all paying its short term obligations.
REPL has a Quick ratio of 13.46. This is amongst the best in the industry. REPL outperforms 86.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.46 | ||
| Quick Ratio | 13.46 |
3. Growth
3.1 Past
REPL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.10%.
EPS 1Y (TTM)-10.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
REPL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.58% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.63%
EPS Next 2Y8.67%
EPS Next 3Y13.19%
EPS Next 5Y14.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for REPL. In the last year negative earnings were reported.
Also next year REPL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
REPL's earnings are expected to grow with 13.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.67%
EPS Next 3Y13.19%
5. Dividend
5.1 Amount
No dividends for REPL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REPLIMUNE GROUP INC
NASDAQ:REPL (9/6/2024, 8:00:02 PM)
After market: 10.88 +0.51 (+4.92%)10.37
-0.35 (-3.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap708.48M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.13% | ||
| ROE | -51.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.46 | ||
| Quick Ratio | 13.46 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-10.1%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y3.63%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y